Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

tock issuable upon conversion of the notes, nor shall there be any offer, solicitation or sale of any securities, including any notes or any shares of the Company's common stock issuable upon conversion of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"), which include, among other things, those concerning whether or not the Company will offer the notes or consummate the proposed offering, the final terms of the notes and the proposed offering, prevailing market conditions, the anticipated principal amount of the notes and the anticipated use of the proceeds of the proposed offering.  The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Act.  Forward-looking statements may be ident
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... , , DUBLIN, Ohio, ... to acquire the assets of privately held Biotech, an operator ... the Southwestern United States. , , Cardinal ... pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These ...
... ... for Jatropha Promotion & Biodiesel (CJP) a big breakthrough in the search for a viable ... of successful field trials, CJP is now happy to announce the much awaited commercial release ... ...
... ... Terrosa Technologies, a provider of Cloud and SaaS migration services ... sales, marketing and distribution responsibilities with Integrated Clinical Solutions for ... Trial Management System (CTMS) tool for the pharmaceutical clinical research ...
Cached Biology Technology:Cardinal Health Completes Biotech Acquisition 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3
(Date:7/24/2014)... arose have been maintained in our cells today according to ... today in the Journal of Biological Chemistry reveals ... animals still perform ancient reactions thought to have been responsible ... ago. , The primordial soup theory suggests that life began ... combination of metals, gases from the atmosphere and some form ...
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... turtles have been slow to give up the secrets ... For decades, paleontologists who study fossils and molecular biologists ... more closely related to birds and crocodiles or to ... Biological Laboratory in Bar Harbor, Maine, and their colleagues ...
... Bethesda, Md. (July 25, 2011)It,s no secret that ... a bevy of recent research suggests that these positive ... a new review article highlighting the results of more ... this topic, Michelle W. Voss, of the University of ...
... One of the latest attempts to boost the ... in which patients receive a therapeutic injection of their ... clinical trials for melanoma and neuroblastoma, has its limitations: ... outside the body for future re-injection is extremely expensive ...
Cached Biology News:Discovery places turtles next to lizards on family tree 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 3Universal donor immune cells 2
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
... VARIOKLAV 75 S and 135 S steam sterilizers ... bottoms combine the advantages of a double-walled device ... effective deaeration and drying by built-in jacket heater ... fast cooling. The chamber is free of furnishings ...
... Shakers combine high durability and performance ... The patented triple-counterbalanced heavy-duty mechanism ... run with heavy out-of-balance loads. ... contamination. The heavy stainless steel ...
... 4300 System features Saga GT , is ... automates electrophoresis, lane finding, location of standards, ... ,Saga GT is second generation software ... initially developed at the University of Washington ...
Biology Products: